Cataract News and Research RSS Feed - Cataract News and Research

A cataract is a clouding of the lens in the eye that affects vision. Most cataracts are related to aging. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery.

A cataract can occur in either or both eyes. It cannot spread from one eye to the other.
Leica Microsystems and TrueVision 3D Surgical expand relationship into the ophthalmology arena

Leica Microsystems and TrueVision 3D Surgical expand relationship into the ophthalmology arena

TrueVision 3D Surgical, a world leader in neuro and ophthalmic 3D surgical visualization, and Leica Microsystems, a world leader in microscopes and scientific instruments, announced an expansion of their existing partnership into the ophthalmology arena. [More]

Alimera Sciences resubmits New Drug Application for ILUVIEN

Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA). [More]
Research report on global ophthalmology devices market

Research report on global ophthalmology devices market

The "Ophthalmology Devices Market (Optical Coherence Tomography (OCT) Scanner, Fundus Camera, Tonometer, Pachymeter, Perimeter, Slit Lamp, Excimer, YAG Laser, Femtosecond Laser, IOL, Contact Lens) - Competitive Landscape & Global Forecasts to 2018", published by MarketsandMarkets, the ophthalmology devices market inclusive of diagnostic, monitoring and surgical devices is expected to grow at a CAGR of 6.8% to reach $9,466.7 Million by 2018. [More]
Tips to avoid eye irritation and longer-term damage to eyes during allergy season

Tips to avoid eye irritation and longer-term damage to eyes during allergy season

With the advent of spring comes wind and allergy season, which can prove to be challenging for individuals who rely on contact lenses for clearer vision. According to the Asthma and Allergy Foundation of America, approximately 1 out of 5 individuals in the United States suffer from eye allergies, while nearly half of all individuals who wear contact lenses report irritation and discomfort from wearing contacts during allergy season. [More]

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days. [More]

PowerVision develops world's first fluid-based accommodating intraocular lens

PowerVision, Inc., a medical device company developing the world's first fluid-based accommodating intraocular lens, today announced that the first 10 patients have received lens implants in its multi-center clinical study assessing the performance of the lens in cataract patients. [More]
Cataract surgery followed by use of contact lenses may be better solution for infants

Cataract surgery followed by use of contact lenses may be better solution for infants

For adults and children who undergo cataract surgery, implantation of an artificial lens is the standard of care. But a clinical trial suggests that for most infants, surgery followed by the use of contact lenses for several years—and an eventual lens implant—may be the better solution. [More]
Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare. [More]

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO). [More]
Study indicates relationship between multivitamin supplement use and cataract risk in men

Study indicates relationship between multivitamin supplement use and cataract risk in men

Long-term daily multivitamin supplement use may lower cataract risk in men, according to a study of nearly 15,000 male physicians published this month in Ophthalmology, the journal of the American Academy of Ophthalmology [More]

LCA-Vision revenues increase 2.1% to $20.6 million in Q4 2013

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus brand, today announced financial and operating results for the three and 12 months ended December 31, 2013. [More]

Duke University Eye Center ophthalmologist uses ReSure Sealant to perform first cataract surgeries

Terry Kim, MD, Professor of Ophthalmology at Duke University Eye Center, performed the first procedures using the ReSure Sealant on his cataract patients in Durham, North Carolina. The ReSure Sealant is the first FDA-approved sealant for ophthalmic use to seal incisions following cataract surgery. [More]
Nutrition and exercise have significant impact on one's vision

Nutrition and exercise have significant impact on one's vision

With the New Year comes many resolutions, including resolving to exercise more and eat better. While many individuals understand that nutrition and exercise play an important role in helping to prevent diabetes, obesity, and cardiovascular disorders, not many may be aware that these two elements have a significant impact on one's vision as well. Dr. Sandy T. Feldman, a renowned ophthalmologist and corneal expert at Clearview Eye & Laser Center in San Diego, advises patients to examine their physical fitness and eating habits in order to achieve optimum vision. [More]

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme. [More]

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013. [More]

PowerVision closes first tranche of Series D funding

PowerVision, Inc., a private company developing an accommodating intraocular lens, today announced the closing of the first tranche of its Series D funding round with participation from existing investors Venrock, Johnson & Johnson Development Corp., Medtronic, Advanced Technology Ventures, Lexington Capital and Frazier Healthcare Ventures. [More]
Human visual system can retain plasticity even after extended blindness

Human visual system can retain plasticity even after extended blindness

Deprivation of vision during critical periods of childhood development has long been thought to result in irreversible vision loss. [More]

FDA grants final approval for Hi-Tech Pharmacal's Bromfenac Ophthalmic Solution ANDA

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, granted final approval for the Company's Abbreviated New Drug Application, for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%. [More]

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Ocular Therapeutix announced today it has received approval from the Food and Drug Administration to commercialize the ReSure Sealant in the United States, with an indication for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery. [More]

Carl Zeiss Meditec acquires 100% of shares in Aaren Scientific

Carl Zeiss Meditec AG announces it has acquired, through its subsidiary Carl Zeiss Meditec Inc., 100% of the shares in Aaren Scientific Inc., a US-based manufacturer of intraocular lenses (IOLs). Aaren Scientific, headquartered in Ontario, California, has been manufacturing IOLs for more than two decades. The majority of shares in Aaren Scientific had previously been owned by a private investment company as well as other investors, including the CEO and co-founder of Aaren Scientific, Rick Aguilera, who along with the entire management team will stay on board after the transaction. [More]